Wim J. Kruit

Rotterdam, ZH 3000CA, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands.

Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands.

Journal: Melanoma research
Published: April 19, 2021

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

Journal: Cancers
Published: May 27, 2019

Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma.

Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: July 17, 2018

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Journal: Anti-cancer drugs
Published: April 17, 2018

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

Journal: Anti-cancer drugs
Published: April 11, 2018

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

Journal: The Lancet. Oncology
Published: December 19, 2017

Pimasertib-associated ophthalmological adverse events.

Pimasertib-associated ophthalmological adverse events.

Journal: Acta ophthalmologica
Published: August 28, 2017

A medical cause for fifty shades of grey.

A medical cause for fifty shades of grey.

Journal: The Netherlands journal of medicine
Published: August 31, 2016

Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.

Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.

Journal: European journal of cancer (Oxford, England : 1990)
Published: November 12, 2015

The Importance of Long-Term Surveillance of Stage IB Melanomas: Unexpectedly Low Survival Subsequent to Recurrence.

The Importance of Long-Term Surveillance of Stage IB Melanomas: Unexpectedly Low Survival Subsequent to Recurrence.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors.

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors.

Journal: British journal of cancer
Published: September 15, 2014

Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling.

Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling.

Journal: Oncogene
Published: May 16, 2014
Showing 1-12 of 16

Last Updated: 09/26/2026